Chemicals

Amyris to Acquire Sweet-Protein Innovator Oobli

The planned deal combines Amyris’s fermentation manufacturing scale with Oobli’s sweet-protein platform for sugar reduction.

Kavya SridharNovember 16, 20265 min read1 views
A conceptual editorial illustration shows stainless-steel fermentation tanks beside a translucent protein model and rare fruit, linking biomanufacturing with sweet proteins.

Amyris, Inc., an Emeryville, California-based vertically integrated biomanufacturing company, announced that it will acquire Oobli Inc., a Davis, California-based sweet protein innovator. Oobli’s fermentation-based ingredients are designed to help food and beverage brands reduce sugar without sacrificing taste.

The transaction would combine Amyris’s scientific capabilities and manufacturing depth with Oobli’s protein fermentation expertise. Amyris said the move follows its expansion of manufacturing capacity earlier this year at its advanced fermentation facility in Barra Bonita, Brazil, and represents a strategic commercial and technology expansion. The company expects the deal to accelerate its presence in protein- and peptide-based solutions across end markets.

Complementary platforms

Kathy Fortmann, Amyris’s chief executive officer, described Oobli as a commercial and technology platform that complements Amyris. She said Oobli is positioned to change how sweetness reaches the market, and that Amyris aims to add commercial scale and resources to accelerate that effort. Fortmann said combining Oobli’s protein expertise with Amyris’s strain engineering, manufacturing scale and commercial capabilities could broaden offerings in food and beverage, personal care, flavor and fragrance, agriculture and other areas.

Oobli’s commercial sweet protein portfolio is expected to be the first to benefit from the combined platform. Oobli spent the past decade refining a fermentation process to produce sweet proteins naturally found in rare fruits and berries near the equator. According to the announcement, sweet proteins are hundreds to thousands of times sweeter than sugar, bind directly to sweet taste receptors and are metabolized by the body as protein, delivering sweetness without gut disruption or blood sugar spikes.

Oobli’s portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit sweet proteins, known scientifically as brazzein, monellin and thaumatin, respectively. The portfolio has FDA GRAS status as an ingredient and is FEMA GRAS-affirmed for use as a natural flavor. With growing consumer awareness of metabolic health and sugar reduction, the companies see sweet proteins as a tool for brands across sports and nutrition, dairy, beverages, chocolate, bakery and confectionery.

Ali Wing, Oobli’s chief executive officer, said the company has long believed there was a better way to deliver the sweet taste consumers want without trade-offs to health and the environment. Wing said joining Amyris would give Oobli the scale and resources to pursue its ambition of making sweet proteins a global standard in sweetness solutions.

Fortmann added that Amyris has seen biomanufactured solutions succeed when they align with consumer demand and market needs, and said Oobli’s platform does that by giving brands a way to address sweet taste, sugar reduction and clean label at the same time. She said Amyris is excited to welcome the Oobli team.

The acquisition is expected to close in the coming weeks. Amyris said all existing customer commitments and brand partnerships will continue to be honored without interruption as Oobli’s portfolio expands within the company.